Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. - Enterprise Valueverified

RNAC

Price:

$7.42

Market Cap:

$218.01M

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-...[Read more]

Industry

Biotechnology

IPO Date

2016-06-22

Stock Exchange

NASDAQ

Ticker

RNAC

The Enterprise Value as of July 2026 (TTM) for Cartesian Therapeutics, Inc. (RNAC) is 111.22M

According to Cartesian Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 111.22M. This represents a change of 13.75% compared to the average of 97.78M of the last 4 quarters.

Cartesian Therapeutics, Inc. (RNAC) Historical Enterprise Value (quarterly & annually)

How has RNAC Enterprise Value performed in the past?

The mean historical Enterprise Value of Cartesian Therapeutics, Inc. over the last ten years is 110.14M. The current 111.22M Enterprise Value has changed 10.00% with respect to the historical average. Over the past ten years (40 quarters), RNAC's Enterprise Value was at its highest in in the September 2021 quarter at 399.78M. The Enterprise Value was at its lowest in in the June 2016 quarter at -32003841.62.

Quarterly (TTM)
Annual

Average

110.14M

Median

89.08M

Minimum

19.44M

Maximum

265.33M

Cartesian Therapeutics, Inc. (RNAC) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cartesian Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 682.80%

Maximum Annual Enterprise Value = 265.33M

Minimum Annual Increase = -71.81%

Minimum Annual Enterprise Value = 19.44M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202574.80M-71.81%
2024265.33M643.39%
202335.69M-47.36%
202267.80M-70.75%
2021231.82M52.31%
2020152.20M682.80%
201919.44M-42.15%
201833.61M-71.35%
2017117.32M13.50%
2016103.36M-20.27%

Cartesian Therapeutics, Inc. (RNAC) Average Enterprise Value

How has RNAC Enterprise Value performed in the past?

The current Enterprise Value of Cartesian Therapeutics, Inc. (RNAC) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

125.28M

5-year avg

135.09M

10-year avg

110.14M

Cartesian Therapeutics, Inc. (RNAC) Enterprise Value vs. Peers

How is RNAC’s Enterprise Value compared to its peers?

Cartesian Therapeutics, Inc.’s Enterprise Value is less than Eupraxia Pharmaceuticals Inc. (157.83M), less than Inventiva S.A. (507.06M), less than Nautilus Biotechnolgy, Inc. (146.81M), less than Orchestra BioMed Holdings, Inc. (232.81M), less than MediWound Ltd. (147.82M), greater than Aardvark Therapeutics, Inc. Common Stock (54.32M), less than Fennec Pharmaceuticals Inc. (295.03M), less than Avalo Therapeutics, Inc. (192.04M), greater than Neonc Technologies Holdings, Inc. (90.97M), less than Genfit S.A. (729.68M),

Build a custom stock screener for Cartesian Therapeutics, Inc. (RNAC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cartesian Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cartesian Therapeutics, Inc. (RNAC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cartesian Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Cartesian Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Cartesian Therapeutics, Inc. (RNAC)?

What is the 3-year average Enterprise Value for Cartesian Therapeutics, Inc. (RNAC)?

What is the 5-year average Enterprise Value for Cartesian Therapeutics, Inc. (RNAC)?

How does the current Enterprise Value for Cartesian Therapeutics, Inc. (RNAC) compare to its historical average?